// Real-Time Intelligence Feed

Financial Intelligence.
Real-Time.

SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.

22,614
Stories Indexed
Live
Feed Status
6
Data Sources
LATEST
AllEarningsFDAM&AInsider TradingRegulatoryOfferingLeadershipRestructuringDividendInstitutional HoldingsBankruptcy
FDA · 22,614 results Live
FDA Alembic Jun 11 — 0.00

FDA Approves TRETINOIN — Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited announced a competitive win with the FDA approval of its Tretinin topical ANDA, allowing it to enter the market and challenge established players am…

FDA Saptalis Jun 11 — 0.00

FDA Approves HYDROXYZINE HYDROCHLORIDE — Saptalis Pharmaceuticals, LLC.

**June 11, 2026** – Saptalis Pharmaceuticals, LLC has received FDA approval for its Abbreviated New Drug Application (ANDA 220271) for Oral Hydroxyzine Hydrochloride. This win is e…

FDA Aurobindo Jun 9 — 0.00

FDA Approves CEPHALEXIN — Aurobindo Pharma Limited

# FDA Approves Aurobindo Pharma's Cephalexin Oral Formulation The U.S. Food and Drug Administration has approved Aurobindo Pharma Limited's abbreviated new drug application (ANDA2…

FDA Orient Jun 9 — 0.00

FDA Approves TOFACITINIB — Orient Pharma Co., Ltd. Yunlin Plant

Orient Pharma Co., Ltd. has received FDA approval for its ANDA to manufacture tofacitinib citrate oral tablets, a move that signals the company’s entry into the lucrative rheumatol…

FDA RADIOMEDIX Jun 8 — 0.00

FDA Approves Unknown Drug — RADIOMEDIX

# FDA Approves Radiopharmaceutical Generic from Radiomedix The FDA approved Radiomedix's generic radiopharmaceutical application (ANDA216410) on June 8, 2026, positioning the comp…

FDA Amneal Jun 8 — 0.00

FDA Approves MACITENTAN — Amneal Pharmaceuticals NY LLC

Amneal Pharmaceuticals NY LLC secured FDA approval for oral MACITENTAN on June 8, 2026, a strategic move expected to diversify the company’s portfolio and intensify competition wit…

FDA HIBROW Jun 4 — 0.00

FDA Approves Unknown Drug — HIBROW HLTHCARE

HIBROW HLTHCARE announced FDA approval for ANDA 215485, a strategic regulatory milestone that advances the company's generic pipeline toward a 2026 delivery. Market analysts are li…

FDA MSN Jun 4 — 0.00

FDA Approves Unknown Drug — MSN

MSN Pharmaceuticals received FDA approval for its ANDA213703, signaling the company's subsequent entry into the specific market. This clearance positions MSN to capitalize on the d…

FDA Somerset Jun 3 — 0.00

FDA Approves TOFACITINIB — Somerset Therapeutics, LLC

# FDA Approves Generic Tofacitinib; Somerset Therapeutics Enters Competitive JAK Inhibitor Market Somerset Therapeutics, LLC has received FDA approval for its generic tofacitinib …

FDA Novadoz Jun 3 — 0.00

FDA Approves TOFACITINIB — Novadoz Pharmaceuticals LLC

# FDA Approves Generic Tofacitinib from Novadoz Pharmaceuticals Novadoz Pharmaceuticals LLC has received FDA approval for its generic tofacitinib citrate oral formulation, marking…

FDA Sun Jun 3 — 0.00

FDA Approves TOFACITINIB — Sun Pharmaceutical Industries, Inc.

Sun Pharmaceutical Industries has received FDA approval for its generic tofacitinib citrate oral formulation, a regulatory milestone expected to drive revenue growth as the company…

FDA Breckenridge Jun 3 — 0.00

FDA Approves TOFACITINIB — Breckenridge Pharmaceutical, Inc.

Breckenridge Pharmaceutical’s FDA approval for oral tofacitinib citrate is set to introduce aggressive competition to the branded market, likely pressuring the sole brand-name entr…

FDA Aurobindo Jun 3 — 0.00

FDA Approves TOFACITINIB — Aurobindo Pharma Limited

Aurobindo Pharma received FDA approval for its generic tofacitinib citrate oral tablets on June 3, 2026, establishing a new entrant in the JAK inhibitor market. This authorization …

FDA Novadoz Jun 3 — 0.00

FDA Approves TOFACITINIB — Novadoz Pharmaceuticals LLC

Novadoz Pharmaceuticals secured FDA approval June 3, 2026, for oral Tofacitinib Citrate tablets, positioning the firm to capitalize on a significant rheumatoid arthritis market. Th…

FDA SPECGX Jun 3 — 0.00

FDA Approves Unknown Drug — SPECGX LLC

SpecGx LLC has received FDA approval for ANDA 219395, signaling an imminent opportunity for the company to enter the market with the companion diagnostic product. This regulatory m…

FDA Apotex Jun 3 — 0.00

FDA Approves TOFACITINIB — Apotex Corp.

Apotex has secured FDA approval for the generic version of tofacitinib (ANDA218096), slated for release on June 3, 2026, which is set to intensify commercial competition and exert …

FDA Amneal Jun 2 — 0.00

FDA Approves ROMIDEPSIN — Amneal Pharmaceuticals LLC

# FDA Approves Generic Romidepsin from Amneal Pharmaceuticals Amneal Pharmaceuticals LLC has received FDA approval for generic romidepsin intravenous formulation, expanding the co…

FDA CASPER Jun 2 — 0.00

FDA Approves Unknown Drug — CASPER PHARMA LLC

Casper Pharma LLC has secured FDA approval for its generic drug application (NDA212927), slated for issuance on June 2, 2026. This regulatory clearance is expected to alter market …

FDA Zydus Jun 1 — 0.00

FDA Approves FLUORESCEIN — Zydus Pharmaceuticals USA Inc.

# FDA Approves Zydus Pharmaceuticals' Generic Fluorescein Sodium Injection Zydus Pharmaceuticals USA Inc. received FDA approval for its generic fluorescein sodium intravenous inje…

FDA CONCORD Jun 1 — 0.00

FDA Approves Unknown Drug — CONCORD BIOTECH LTD

Concord Biotech Ltd’s FDA approval of ANDA218566 is expected to enhance the company’s long-term market position and revenue potential, paving the way for strategic commercial activ…